NO329784B1 - Fremgangsmate for a redusere homologe rekombinasjonsfenomener, defekte rekombinante adenovirus og cellelinje. - Google Patents

Fremgangsmate for a redusere homologe rekombinasjonsfenomener, defekte rekombinante adenovirus og cellelinje. Download PDF

Info

Publication number: NO329784B1
Authority: NO; Norway
Prior art keywords: sequence; adenovirus; region; genome; degenerate
Prior art date: 1997-11-17

Application number

NO20002504A

Other languages

English (en)

Norwegian (no)

Other versions

NO20002504D0 (no

NO20002504L (no

Inventor

Emmanuelle Vigne

Jean-Jacques Robert

Joel Crouzet

Patrice Yeh

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-17

Filing date

2000-05-15

Publication date

2010-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9513447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO329784(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-15 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2000-05-15 Publication of NO20002504D0 publication Critical patent/NO20002504D0/no

2000-05-15 Publication of NO20002504L publication Critical patent/NO20002504L/no

2010-12-20 Publication of NO329784B1 publication Critical patent/NO329784B1/no

Links

230000002950 deficient Effects 0.000 title claims abstract description 43
238000000034 method Methods 0.000 title claims abstract description 42
241000701161 unidentified adenovirus Species 0.000 title claims description 85
230000006801 homologous recombination Effects 0.000 title claims description 39
238000002744 homologous recombination Methods 0.000 title claims description 39
150000007523 nucleic acids Chemical class 0.000 claims abstract description 67
108020004707 nucleic acids Proteins 0.000 claims abstract description 63
102000039446 nucleic acids Human genes 0.000 claims abstract description 63
238000004519 manufacturing process Methods 0.000 claims abstract description 17
108090000623 proteins and genes Proteins 0.000 claims description 70
101150032643 IVa2 gene Proteins 0.000 claims description 36
230000004048 modification Effects 0.000 claims description 20
238000012986 modification Methods 0.000 claims description 20
108020004705 Codon Proteins 0.000 claims description 14
230000002759 chromosomal effect Effects 0.000 claims description 12
238000012217 deletion Methods 0.000 claims description 10
230000037430 deletion Effects 0.000 claims description 10
108091026890 Coding region Proteins 0.000 claims description 9
230000007850 degeneration Effects 0.000 claims description 5
230000007547 defect Effects 0.000 claims description 4
108700026244 Open Reading Frames Proteins 0.000 claims description 2
230000006798 recombination Effects 0.000 abstract description 43
238000005215 recombination Methods 0.000 abstract description 41
241000700605 Viruses Species 0.000 abstract description 30
230000003612 virological effect Effects 0.000 abstract description 15
239000002245 particle Substances 0.000 abstract description 11
230000010076 replication Effects 0.000 abstract description 8
210000004027 cell Anatomy 0.000 description 56
239000013612 plasmid Substances 0.000 description 32
101150057615 Syn gene Proteins 0.000 description 30
239000013598 vector Substances 0.000 description 25
230000014509 gene expression Effects 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 18
239000012634 fragment Substances 0.000 description 16
239000002773 nucleotide Substances 0.000 description 16
125000003729 nucleotide group Chemical group 0.000 description 16
108020004414 DNA Proteins 0.000 description 11
241001135569 Human adenovirus 5 Species 0.000 description 11
238000010276 construction Methods 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
230000003362 replicative effect Effects 0.000 description 9
108091028043 Nucleic acid sequence Proteins 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000006870 function Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
239000013603 viral vector Substances 0.000 description 7
125000003275 alpha amino acid group Chemical group 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000012795 verification Methods 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 5
101150066555 lacZ gene Proteins 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
241001430294 unidentified retrovirus Species 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108700039691 Genetic Promoter Regions Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
230000003321 amplification Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
230000008488 polyadenylation Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
101100165660 Alternaria brassicicola bsc6 gene Proteins 0.000 description 2
-1 ApoAIV Proteins 0.000 description 2
101100499295 Bacillus subtilis (strain 168) disA gene Proteins 0.000 description 2
101100243951 Caenorhabditis elegans pie-1 gene Proteins 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
241000701533 Escherichia virus T4 Species 0.000 description 2
241000598171 Human adenovirus sp. Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
101150007210 ORF6 gene Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
101100226894 Phomopsis amygdali PaGT gene Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000011109 contamination Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000005782 double-strand break Effects 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
230000007170 pathology Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000037432 silent mutation Effects 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
102100022464 5'-nucleotidase Human genes 0.000 description 1
208000010370 Adenoviridae Infections Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
241000282465 Canis Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102100038909 Caveolin-2 Human genes 0.000 description 1
208000037088 Chromosome Breakage Diseases 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
208000000655 Distemper Diseases 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000004038 Glia Maturation Factor Human genes 0.000 description 1
108090000495 Glia Maturation Factor Proteins 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108090000742 Neurotrophin 3 Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
101710143509 Pre-histone-like nucleoprotein Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
102100032889 Sortilin Human genes 0.000 description 1
108700026226 TATA Box Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
208000014058 canine distemper Diseases 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000009962 secretion pathway Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Virology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Control Of Motors That Do Not Use Commutators (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Ticket-Dispensing Machines (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Battery Electrode And Active Subsutance (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20002504A 1997-11-17 2000-05-15 Fremgangsmate for a redusere homologe rekombinasjonsfenomener, defekte rekombinante adenovirus og cellelinje. NO329784B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9714383A FR2774699B1 (fr)	1997-11-17	1997-11-17	Methode de reduction des evenements de recombinaison homologue
PCT/FR1998/002453 WO1999025861A2 (fr)	1997-11-17	1998-11-17	Vecteurs adenoviraux et methode de reduction des evenements de recombinaison homologue

Publications (3)

Publication Number	Publication Date
NO20002504D0 NO20002504D0 (no)	2000-05-15
NO20002504L NO20002504L (no)	2000-05-15
NO329784B1 true NO329784B1 (no)	2010-12-20

Family

ID=9513447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20002504A NO329784B1 (no)	1997-11-17	2000-05-15	Fremgangsmate for a redusere homologe rekombinasjonsfenomener, defekte rekombinante adenovirus og cellelinje.

Country Status (17)

Country	Link
US (1)	US6410298B1 (de)
EP (1)	EP1032695B1 (de)
JP (1)	JP4376454B2 (de)
KR (2)	KR20070103483A (de)
CN (1)	CN1201013C (de)
AT (1)	ATE393234T1 (de)
AU (1)	AU759531B2 (de)
BR (1)	BR9814210A (de)
CA (1)	CA2309315C (de)
CZ (1)	CZ299797B6 (de)
DE (1)	DE69839403T2 (de)
FR (1)	FR2774699B1 (de)
HU (1)	HU226018B1 (de)
IL (2)	IL135983A0 (de)
NO (1)	NO329784B1 (de)
PL (1)	PL196606B1 (de)
WO (1)	WO1999025861A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2799472B1 (fr) *	1999-10-07	2004-07-16	Aventis Pharma Sa	Preparation d'adenovirus recombinants et de banques adenovirales
US6821775B1 (en) *	2000-02-11	2004-11-23	Genvec, Inc.	Viral vector encoding pigment epithelium-derived factor
US7653769B2 (en) *	2006-12-14	2010-01-26	International Business Machines Corporation	Management of devices connected to infiniband ports
US6591543B2 (en) *	2000-04-14	2003-07-15	Kenneth P. Sabine	Top water lure with highly active propeller
KR20010064682A (ko) *	2000-07-01	2001-07-11	김재호	Ｅ1ｂ가 감쇠된 아데노바이러스를 이용한 ｃｄ／5－ｆｃ및 ｈｓｖ－1 ｔｋ／ｇｃｖ의 이중 자멸 유전자 시스템
DE10045687B4 (de) *	2000-09-15	2006-07-06	MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald	Expressionskassetten und Adenovirusvektoren
US20030087438A1 (en) *	2001-11-02	2003-05-08	Genvec, Inc.	E1-revertant-free adenoviral composition
US20030158112A1 (en)	2002-02-15	2003-08-21	Johns Hopkins University School Of Medicine	Selective induction of apoptosis to treat ocular disease
JP2006516027A (ja) *	2002-12-02	2006-06-15	ジェンベク、インコーポレイティッド	眼関連障害の治療用材料および治療方法
CA2559436A1 (en) *	2004-03-12	2005-09-29	Genvec, Inc.	Materials for treating vascular leakage in the eye
US20060188481A1 (en) *	2005-02-22	2006-08-24	Saitama Medical School	Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
CL2008000249A1 (es) *	2007-01-30	2008-05-30	Transgene Sa	Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
KR101514473B1 (ko) *	2007-05-15	2015-04-22	트랜스진 에스.에이.	다중 유전자 발현용 벡터
HUE029744T2 (en)	2007-07-26	2017-04-28	Uniqure Ip Bv	Baculoviral vectors comprising repeated coding sequences with differential codon biases
EP2352834B1 (de) *	2008-11-21	2016-12-21	Bavarian Nordic A/S	Virus bestehend aus nucleotidesequenzen kodierend für multipel homologen
EP2389443B1 (de)	2009-01-23	2018-11-14	Roger Williams Hospital	Retrovirale vektoren kodierend für multiple stark homologe nichtvirale polypeptide und ihre verwendung
WO2012021730A2 (en) *	2010-08-11	2012-02-16	Genvec, Inc.	Respiratory syncytial virus (rsv) vaccine
US9404090B2 (en)	2011-11-24	2016-08-02	Viromed Co., Ltd.	Adenovirus producing novel cell line and the use thereof
US9014637B1 (en) *	2013-09-27	2015-04-21	Intel Corporation	Dynamic switching frequency control of an on-chip or integrated voltage regulator
CN108203706B (zh) *	2017-11-30	2021-03-26	陕西师范大学	一种用于提高高容量腺病毒包装效率的辅助腺病毒
CN112877358B (zh) *	2021-02-07	2023-02-03	上海市第一人民医院	一种基于5型腺病毒序列的重组质粒及应用
CN119432919B (zh) *	2024-11-12	2025-07-01	北京因美未来生物医药科技有限公司	减少复制型腺病毒污染的病毒载体及构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2726285B1 (fr) *	1994-10-28	1996-11-29	Centre Nat Rech Scient	Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
ATE386130T1 (de) *	1995-03-24	2008-03-15	Genzyme Corp	Adenovirale vektoren für die gentherapie
DE69633565T3 (de) *	1995-06-15	2013-01-17	Crucell Holland B.V.	Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie

1997
- 1997-11-17 FR FR9714383A patent/FR2774699B1/fr not_active Expired - Fee Related
1998
- 1998-11-17 HU HU0101827A patent/HU226018B1/hu not_active IP Right Cessation
- 1998-11-17 IL IL13598398A patent/IL135983A0/xx active IP Right Grant
- 1998-11-17 AT AT98955679T patent/ATE393234T1/de not_active IP Right Cessation
- 1998-11-17 EP EP98955679A patent/EP1032695B1/de not_active Expired - Lifetime
- 1998-11-17 CZ CZ20001791A patent/CZ299797B6/cs not_active IP Right Cessation
- 1998-11-17 CN CNB98810749XA patent/CN1201013C/zh not_active Expired - Fee Related
- 1998-11-17 JP JP2000521224A patent/JP4376454B2/ja not_active Expired - Fee Related
- 1998-11-17 CA CA2309315A patent/CA2309315C/fr not_active Expired - Fee Related
- 1998-11-17 BR BR9814210-0A patent/BR9814210A/pt not_active IP Right Cessation
- 1998-11-17 US US09/530,378 patent/US6410298B1/en not_active Expired - Lifetime
- 1998-11-17 KR KR1020077020673A patent/KR20070103483A/ko not_active Ceased
- 1998-11-17 WO PCT/FR1998/002453 patent/WO1999025861A2/fr not_active Ceased
- 1998-11-17 DE DE69839403T patent/DE69839403T2/de not_active Expired - Lifetime
- 1998-11-17 KR KR1020007005333A patent/KR100796060B1/ko not_active Expired - Fee Related
- 1998-11-17 PL PL340601A patent/PL196606B1/pl unknown
2000
- 2000-05-03 AU AU31294/00A patent/AU759531B2/en not_active Ceased
- 2000-05-04 IL IL135983A patent/IL135983A/en not_active IP Right Cessation
- 2000-05-15 NO NO20002504A patent/NO329784B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1999025861A2 (fr)	1999-05-27
CN1201013C (zh)	2005-05-11
PL196606B1 (pl)	2008-01-31
FR2774699B1 (fr)	2003-10-03
BR9814210A (pt)	2000-10-03
KR100796060B1 (ko)	2008-01-21
CZ20001791A3 (cs)	2000-08-16
IL135983A (en)	2008-11-26
CA2309315A1 (fr)	1999-05-27
AU759531B2 (en)	2003-04-17
EP1032695A2 (de)	2000-09-06
KR20010032146A (ko)	2001-04-16
US6410298B1 (en)	2002-06-25
NO20002504D0 (no)	2000-05-15
WO1999025861A3 (fr)	1999-07-01
NO20002504L (no)	2000-05-15
FR2774699A1 (fr)	1999-08-13
HUP0101827A2 (hu)	2001-09-28
EP1032695B1 (de)	2008-04-23
DE69839403T2 (de)	2009-05-28
HUP0101827A3 (en)	2003-08-28
JP2003504004A (ja)	2003-02-04
HU226018B1 (en)	2008-03-28
CA2309315C (fr)	2011-06-14
AU3129400A (en)	2000-12-14
CN1278302A (zh)	2000-12-27
JP4376454B2 (ja)	2009-12-02
ATE393234T1 (de)	2008-05-15
KR20070103483A (ko)	2007-10-23
IL135983A0 (en)	2001-05-20
CZ299797B6 (cs)	2008-11-26
PL340601A1 (en)	2001-02-12
DE69839403D1 (de)	2008-06-05

Legal Events

Date	Code	Title	Description
2010-12-20	CREP	Change of representative	Representative=s name: EHRNER & DELMAR PATENTBYRA AB, BOX
2011-05-16	CREP	Change of representative	Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA
2015-06-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
Parks et al.	2000	An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method
US6482617B2 (en)	2002-11-19	Viable contaminant particle free adenoviruses, their preparation and use
EP0996735B1 (de)	2003-12-10	Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
JP4376454B2 (ja)	2009-12-02	アデノウイルスベクター及び相同組換えイベントの低減方法
JP3842818B2 (ja)	2006-11-08	組換えアデノウイルスゲノムの製造方法
NO320818B1 (no)	2006-01-30	Rekombinant adenovirus av ikke-human, animalsk opprinnelse, farmasoytisk preparat omfattende dette samt anvendelse av adenoviruset.
MXPA00012617A (es)	2002-08-20	Adenovirus recombinante con replicacion defectuosa con un promotor tardio principal mutado.
EP0988389A1 (de)	2000-03-29	Methode für die produktion von adenoviralen vektoren, die nicht vom serotyp c abgeleitet sind
JP3827163B2 (ja)	2006-09-27	遺伝子治療用のアデノウイルスベクター
Mittal et al.	1995	Foreign gene expression by human adenovirus type 5-based vectors studied using firefly luciferase and bacterial β-galactosidase genes as reporters
AU770005B2 (en)	2004-02-12	Selective regulation of adenovirus production
NO319055B1 (no)	2005-06-13	Defekte, rekombinante adenoviruser med inaktivt IVa2-gen
Lu et al.	2013	Enhanced growth of recombinant human adenovirus type 41 (HAdV-41) carrying ADP gene
Gall et al.	2007	Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes
JP2004519201A (ja)	2004-07-02	キメラアデノウイルスベクター
NO330916B1 (no)	2011-08-15	Fremstilling av rekombinante adenovirus og et kit som inneholder plasmider med avkortede adenovirusgenom.
CN118308427B (zh)	2024-09-27	一种应用于多种构建体系的重组腺病毒载体质粒及其构建方法和应用
CN113774031B (zh)	2024-04-02	一种复制型人腺病毒及其应用
US7264818B2 (en)	2007-09-04	BAV packaging regions and E1 transcriptional control regions
CN101363028A (zh)	2009-02-11	互补型高容量腺病毒载体系统及其构建的疫苗和基因治疗产品
US7687615B2 (en)	2010-03-30	PAV regions for encapsidation and E1 transcriptional control
AU2002313348B2 (en)	2006-12-07	Method for preparing a recombinant adenovirus genome
MXPA00004646A (en)	2002-02-26	Adenovirus vectors and method for reducing homologous recombination phenomena